Metagenomi Therapeutics (MGX) Change in Account Payables (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Change in Account Payables of $795000.0 for Q1 2026, down 64.03% year-over-year from $2.2 million in Q1 2025, and up 129.77% quarter-over-quarter from $346000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Change in Account Payables (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Change in Account Payables for 4 consecutive years, with $795000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 64.03% year-over-year to $795000.0; the TTM figure through Mar 2026 stood at -$361000.0 (up 82.43% YoY), while the FY2025 annual figure was $1.1 million, up 195.3% from the prior year.
- Change in Account Payables grew to $795000.0 in Q1 2026 per MGX's latest filing, from $346000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.2 million in Q1 2024 and bottomed at -$2.6 million in Q4 2024.
- Historically, Change in Account Payables has averaged $50692.3 across 4 years, with a median of $74000.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Account Payables surged 162.16% — and 2025, when it slumped 483.7%.
- Metagenomi Therapeutics' Change in Account Payables stood at -$2.5 million in 2023, then fell by 1.86% to -$2.6 million in 2024, then soared by 113.46% to $346000.0 in 2025, then surged by 129.77% to $795000.0 in 2026.
- Business Quant data shows MGX's Change in Account Payables at $795000.0 in Q1 2026, $346000.0 in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 319,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 319,000.00 |
| Jun 30, 2026 | 319,000.00 |
| Mar 31, 2026 | 795,000.00 |
| Mar 31, 2026 | 795,000.00 |
| Dec 31, 2025 | 346,000.00 |
| Dec 31, 2025 | 346,000.00 |
| Sep 30, 2025 | -1.58 Mn |
| Sep 30, 2025 | -1.58 Mn |
| Jun 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Dec 31, 2024 | -2.57 Mn |
| Sep 30, 2024 | -270,000.00 |
| Sep 30, 2024 | -270,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Mar 31, 2024 | 3.16 Mn |